Epinephrine oromucosal film - Klaria/Purdue Pharma
Alternative Names: Adrenaline alginate film - Imbrium Therapeutics/Klaria AB; Adrenaline oromucosal film - Imbrium Therapeutics/Klaria AB; Epinephrine alginate film - Imbrium Therapeutis/Klaria AB; Epinephrine oral trans-mucosal film - Klaria; Epinephrine oromucosal film - Imbrium Therapeutics/Klaria AB; KL 01401Latest Information Update: 15 Mar 2022
At a glance
- Originator Klaria AB
- Developer Imbrium Therapeutics; Klaria AB
- Class Anti-infectives; Antiallergics; Antiasthmatics; Bronchodilators; Catecholamines; Ethanolamines; Skin disorder therapies; Small molecules
- Mechanism of Action Alpha adrenergic receptor agonists; Beta-adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Anaphylaxis
Most Recent Events
- 15 Mar 2022 Phase-I clinical trials in Anaphylaxis in Sweden (Buccal) (Imbrium Therapeutics pipeline, March 2022)
- 15 Mar 2022 Phase-I clinical trials in Anaphylaxis in USA (Buccal) (Imbrium Therapeutics pipeline, March 2022)